#chlebowski

[rapidhighway]

with that name, i'd trust him

[polishpaintersonly]

“Portrait of an Unknown Woman“ (1867) by Stanisław Chlebowski (Polish;1835-1884)

oil on canvas

Hermitage Museum

[poderwanie]

@lastdreams

[junck-ritter]

Here is a design for one of the t-shirts you can get when you come to FotS.

[paylolorens-blog]

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer. Bone-building drugs known as bisphosphonates appear to break the jeopardy of invasive heart of hearts cancer by around 30 percent, two uncharted studies show. "If a woman is considering bisphosphonate use for bone, this might be another potential benefit," said Dr Rowan T Chlebowski, a clinical oncologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance, Calif vitobest.men. He is the show the way writer of one of the two studies on the topic, published online this week in the Journal of Clinical Oncology. The findings were pre-eminent presented departed last year at the San Antonio Breast Cancer Symposium, but Chlebowski said the results now have the better of having been peer-reviewed before publication for scientific accuracy neosizeplus men. Chlebowski and his colleagues looked at nearly 155000 women who participated in the Women's Health Initiative (WHI) study, evaluating the 2816 women who took viva voce bisphosphonates at the bone up start and comparing them to women who did not. Ninety percent of the women who were taking the bone-building drugs took alendronate (Fosamax), according to the study. After nearly eight years of follow-up, Chlebowski found invasive titty cancer occurrence was 32 percent deign in those on bone-building drugs, with ER-positive cancers reduced by 30 percent family of albizia lebbeck. The incidence of ER-negative cancers in those on bisphosphonates also decreased, but not by enough to be statistically significant. The amount of early, noninvasive breast cancers, known as ductal carcinoma in situ, was 42 percent higher in bisphosphonate users, so the bisphosphonates could by fair means be selectively affecting invasive cancers, Chlebowski postulated. In a double study, conducted in Israel, researchers looked at 4039 postmenopausal women, including some who took bisphosphonates and some who did not. Those who took the hypnotic longer than a year had a 39 percent reduced gamble of boob cancer; after adjusting for factors such as age and family history, there was still a risk reduction of 28 percent. Exactly how the drugs mitigate risk isn't known. Chlebowski speculated that the drugs may close off the release of growth factors that would encourage tumors to grow or may block blood vessel founding within a tumor. It's known that low bone mineral density (BMD) is linked with a reduced risk of teat cancer, and women with low BMD are likely to be on the drugs. So for the study analysis, Chlebowski adjusted for this reachable confounding effect by incorporating a hip fracture risk score to conduct into account the bone mineral differences between drug users and non-users. Another expert, Dr Joanne Mortimer, captain of the women's cancers program at the City of Hope Comprehensive Cancer Center in Duarte, Calif, trenchant out that the studies found an associative link, not a cause-and-effect, so it's not definitive. However "for grass roots with osteoporosis, it's one more reason to feel comfortable taking a bisphosphonate". Like other medications, the drugs have favorable and unfavorable effects. For instance, researchers recently found women on the bone-building drugs can have a higher imperil of an uncommon fracture; that on is being evaluated further. From the two studies, however it appears that "these drugs transformation the environment in such a way that cancer cells are less likely to take root and grow, not only in the bone marrow but away as well". In an accompanying editorial, Dr Michael Gnant, of the Medical University of Vienna, said approaching studies will help pinpoint the benefit of the drugs in mamma cancer incidence reduction and supply more answers as to their best use get more information. Chlebowski reported that he has been a consultant to Novartis and Amgen, which change the bone-building medications.

[kimoramorory]

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer. Bone-building drugs known as bisphosphonates appear to turn the chance of invasive titty cancer by around 30 percent, two rejuvenated studies show. "If a woman is considering bisphosphonate use for bone, this might be another potential benefit," said Dr Rowan T Chlebowski, a clinical oncologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance, Calif proextender4.men. He is the distance originator of one of the two studies on the topic, published online this week in the Journal of Clinical Oncology. The findings were opening presented till last year at the San Antonio Breast Cancer Symposium, but Chlebowski said the results now have the sake of having been peer-reviewed before publication for scientific accuracy united. Chlebowski and his colleagues looked at nearly 155000 women who participated in the Women's Health Initiative (WHI) study, evaluating the 2816 women who took pronounced bisphosphonates at the swat start and comparing them to women who did not. Ninety percent of the women who were taking the bone-building drugs took alendronate (Fosamax), according to the study. After nearly eight years of follow-up, Chlebowski found invasive knocker cancer degree was 32 percent lessen in those on bone-building drugs, with ER-positive cancers reduced by 30 percent pro extender yukuhashi top. The incidence of ER-negative cancers in those on bisphosphonates also decreased, but not by enough to be statistically significant. The prevalence of early, noninvasive breast cancers, known as ductal carcinoma in situ, was 42 percent higher in bisphosphonate users, so the bisphosphonates could somehow be selectively affecting invasive cancers, Chlebowski postulated. In a b study, conducted in Israel, researchers looked at 4039 postmenopausal women, including some who took bisphosphonates and some who did not. Those who took the sedative longer than a year had a 39 percent reduced imperil of teat cancer; after adjusting for factors such as age and family history, there was still a risk reduction of 28 percent. Exactly how the drugs diet risk isn't known. Chlebowski speculated that the drugs may shut off the release of growth factors that would encourage tumors to grow or may block blood vessel institution within a tumor. It's known that low bone mineral density (BMD) is linked with a reduced risk of heart cancer, and women with low BMD are likely to be on the drugs. So for the study analysis, Chlebowski adjusted for this practical confounding effect by incorporating a hip fracture risk score to be involved into account the bone mineral differences between drug users and non-users. Another expert, Dr Joanne Mortimer, administrator of the women's cancers program at the City of Hope Comprehensive Cancer Center in Duarte, Calif, cuspidate out that the studies found an associative link, not a cause-and-effect, so it's not definitive. However "for proletariat with osteoporosis, it's one more reason to feel comfortable taking a bisphosphonate". Like other medications, the drugs have favorable and unfavorable effects. For instance, researchers recently found women on the bone-building drugs can have a higher endanger of an uncommon fracture; that exploration is being evaluated further. From the two studies, however it appears that "these drugs revolution the environment in such a way that cancer cells are less likely to take root and grow, not only in the bone marrow but to another place as well". In an accompanying editorial, Dr Michael Gnant, of the Medical University of Vienna, said following studies will help pinpoint the benefit of the drugs in bosom cancer incidence reduction and supply more answers as to their best use neosizeplus men. Chlebowski reported that he has been a consultant to Novartis and Amgen, which think the bone-building medications.

[culture-biatch]

Did death ever gaze in to your eyes, Mister? It is looking into my eyes everyday I see its glory in everything

[freesearchengines-blog]

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer

Bisphosphonates Are Used In The Construction Of Bones Further Reduce The Risk Of Invasive Breast Cancer. Bone-building drugs known as bisphosphonates appear to diet the chance of invasive teat cancer by around 30 percent, two green studies show. "If a woman is considering bisphosphonate use for bone, this might be another potential benefit," said Dr Rowan T Chlebowski, a clinical oncologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance, Calif natural-breast-success.com. He is the model prime mover of one of the two studies on the topic, published online this week in the Journal of Clinical Oncology. The findings were inception presented unpunctually last year at the San Antonio Breast Cancer Symposium, but Chlebowski said the results now have the further of having been peer-reviewed before publication for scientific accuracy weight. Chlebowski and his colleagues looked at nearly 155000 women who participated in the Women's Health Initiative (WHI) study, evaluating the 2816 women who took articulated bisphosphonates at the meditate on start and comparing them to women who did not. Ninety percent of the women who were taking the bone-building drugs took alendronate (Fosamax), according to the study. After nearly eight years of follow-up, Chlebowski found invasive bust cancer occurrence was 32 percent lop off in those on bone-building drugs, with ER-positive cancers reduced by 30 percent behoshi ki tablet name. The incidence of ER-negative cancers in those on bisphosphonates also decreased, but not by enough to be statistically significant. The amount of early, noninvasive breast cancers, known as ductal carcinoma in situ, was 42 percent higher in bisphosphonate users, so the bisphosphonates could by crook be selectively affecting invasive cancers, Chlebowski postulated. In a double study, conducted in Israel, researchers looked at 4039 postmenopausal women, including some who took bisphosphonates and some who did not. Those who took the sedate longer than a year had a 39 percent reduced peril of tit cancer; after adjusting for factors such as age and family history, there was still a risk reduction of 28 percent. Exactly how the drugs bring down risk isn't known. Chlebowski speculated that the drugs may block the release of growth factors that would encourage tumors to grow or may block blood vessel generation within a tumor. It's known that low bone mineral density (BMD) is linked with a reduced risk of titty cancer, and women with low BMD are likely to be on the drugs. So for the study analysis, Chlebowski adjusted for this credible confounding effect by incorporating a hip fracture risk score to contain into account the bone mineral differences between drug users and non-users. Another expert, Dr Joanne Mortimer, the man of the women's cancers program at the City of Hope Comprehensive Cancer Center in Duarte, Calif, trenchant out that the studies found an associative link, not a cause-and-effect, so it's not definitive. However "for commoners with osteoporosis, it's one more reason to feel comfortable taking a bisphosphonate". Like other medications, the drugs have favorable and unfavorable effects. For instance, researchers recently found women on the bone-building drugs can have a higher jeopardize of an uncommon fracture; that inquiry is being evaluated further. From the two studies, however it appears that "these drugs trade the environment in such a way that cancer cells are less likely to take root and grow, not only in the bone marrow but somewhere else as well". In an accompanying editorial, Dr Michael Gnant, of the Medical University of Vienna, said subsequent studies will help pinpoint the benefit of the drugs in knocker cancer incidence reduction and supply more answers as to their best use pictures. Chlebowski reported that he has been a consultant to Novartis and Amgen, which represent the bone-building medications.